<DOC>
	<DOCNO>NCT00002440</DOCNO>
	<brief_summary>The purpose study see safe effective give 1592U89 plus certain protease inhibitor ( PIs ) HIV-infected patient never treat anti-HIV drug . This study also examine body process drug give together .</brief_summary>
	<brief_title>A Study 1592U89 Combination With Protease Inhibitors HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
	<detailed_description>In Phase II , open-label study patient ( 16 per treatment group ) randomize receive 1592U89 combination one five protease inhibitor : indinavir , saquinavir , ritonavir , nelfinavir , 141W94 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Local treatment Kaposi 's sarcoma . GMCSF , GCSF erythropoietin . Patients must : HIV1 infection document license HIV1 antibody ELISA confirm Western blot detection HIV1 antibody positive HIV1 blood culture . CD4+ cell count &gt; = 100 cells/mm3 within 14 day study drug administration . HIV1 RNA &gt; = 5,000 copies/ml within 14 day study drug administration . No active ongoing AIDSdefining opportunistic infection disease . Signed , inform consent parent legal guardian patient le 18 year age . Prior Medication : Allowed : Local treatment Kaposi 's sarcoma . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malabsorption syndrome , gastrointestinal dysfunction , might interfere drug absorption render patient unable take oral medication . Lifethreatening infection serious medical condition may compromise patient 's safety . Concurrent Medication : Excluded : Other investigational agent . NOTE : Those available Treatment IND expand access program evaluate individually . Chemotherapeutic agent initial 24 week study ( except local treatment Kaposi 's sarcoma ) . Agents document antiHIV activity vitro . Foscarnet . Immunomodulating agent systemic corticosteroid , interleukin , thalidomide , anticytokine agent interferon . Antioxidants . Concurrent Treatment : Excluded : Radiation therapy within first 24 week study . Patients follow prior condition exclude : History clinically relevant pancreatitis hepatitis within last 6 month . Participation investigational HIV1 vaccine trial . Prior Medication : Excluded : Antiretroviral therapy , include reverse transcriptase inhibitor protease inhibitor therapy . Cytotoxic chemotherapeutic agent within 30 day study drug administration . HIV1 vaccine dose within 3 month prior study drug administration . Immunomodulating agent , systemic corticosteroid , interleukin interferon within 30 day study drug administration . Prior Treatment : Excluded : Radiation therapy within 30 day study drug administration . Alcohol illicit drug use may interfere patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Mutation</keyword>
	<keyword>HIV-1 Reverse Transcriptase</keyword>
	<keyword>HIV Protease</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>